Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neoantigen-pulsed autologous dendritic cell vaccine
- Development stage
- Phase 2
- Lead developer
- Peking University Cancer Hospital & Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The neoantigen-pulsed autologous dendritic cell vaccine is a personalized cancer immunotherapy developed by Peking University Cancer Hospital. This therapeutic approach involves identifying patient-specific tumor mutations (neoantigens) through whole-exome and RNA sequencing of tumor and normal tissues. Synthetic peptides or mRNA corresponding to these unique neoantigens are then used to 'pulse' or load autologous dendritic cells (DCs) derived from the patient's own peripheral blood mononuclear cells. These mature, antigen-loaded DCs are subsequently re-infused into the patient, where they act as professional antigen-presenting cells to prime and activate neoantigen-specific CD4+ and CD8+ T cells. This targeted immune response is designed to recognize and eliminate tumor cells while minimizing damage to healthy tissue. The vaccine is currently being evaluated in clinical trials for various advanced solid tumors, including gastric, pancreatic, and biliary tract cancers.
- Other names
- Personalized neoantigen-pulsed DC vaccineNeoantigen-pulsed autologous DC vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on neoantigen-pulsed autologous dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neoantigen-pulsed autologous dendritic cell vaccine.